Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Susan O'Brien, Deborah A. Thomas, MD, Koji Sasaki, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Nitin Jain, MD, Sergernne York, RN, Rebecca Garris, BSc, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2014) 124 (21): 964.

https://doi.org/10.1182/blood.V124.21.964.964

Published: 2014

Journal Articles

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Susan O'Brien, MD, Deborah A. Thomas, MD, Koji Sasaki, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Sergernne York, RN, Rebecca Garris, BSc, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2014) 124 (21): 794.

https://doi.org/10.1182/blood.V124.21.794.794

Published: 2014

Journal Articles

Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL)

Nitin Jain, MD, Susan O'Brien, MD, Deborah A. Thomas, MD, Elias Jabbour, MD, Stefan Faderl, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Sergernne York, RN, Rebecca Garris, BSc, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 1432.

https://doi.org/10.1182/blood.V122.21.1432.1432

Published: 2013

Journal Articles

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

Susan O'Brien, M.D., Deborah A. Thomas, MD, Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, M.D., Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Sergernne York, RN, Rebecca Garris, BSc, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 671.

https://doi.org/10.1182/blood.V120.21.671.671

Published: 2012

Journal Articles

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Susan o'Brien, Deborah A. Thomas, MD, Maro Ohanian, M.D., Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, MD, Elias Jabbour, Michael E. Rytting, MD, Sergernne York, RN, Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Mary Beth Rios, RN, Jorge E. Cortes, Luis Fayad, MD, Robert Tarnai, MT, Sa A. Wang, MD, Richard Champlin, MD, Anjali S. Advani, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 875.

https://doi.org/10.1182/blood.V118.21.875.875

Published: 2011

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

Journal Articles

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Tapan Kadia, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Zeev Estrov, MD, Sherry A. Pierce, RN, BS, Sergernne York, RN, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 2920.

https://doi.org/10.1182/blood.V116.21.2920.2920

Published: 2010

Journal Articles

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Farhad Ravandi, MD, Jeffrey Jorgensen, MD, PhD, Susan O'Brien, MD, Deborah A Thomas, MD, Stefan Faderl, MD, Sergernne York, RN, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Sherry Pierce, RN, BS, Michael Keating, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2458.

https://doi.org/10.1182/blood.V116.21.2458.2458

Published: 2010

NARROW

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL)

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only